- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Anthem Biosciences Limited — Updates, 05-02-2026: Press Release (Revised)
05-02-2026 | 07:37 pm
05-02-2026 | 07:37 pm
Anthem Biosciences reported Q3 & 9MFY26 consolidated results. 9MFY26 revenue reached ₹1,513.4 Cr, with EBITDA up 23% at ₹671.2 Cr (41.5% margins) and PAT at ₹402 Cr. Q3 revenue was ₹423.2 Cr. The company boasts ₹1,231.2 Cr in net cash, anticipating a strong financial year finish.
No comments yet. Be the first to comment!